Aesthet Surg J:注射TSVF可促进早期伤口愈合,减少疤痕形成

2022-07-03 MedSci原创 MedSci原创

伤口愈合和疤痕形成取决于多种因素。鉴于异常疤痕形成的影响,旨在改善疤痕形成的干预措施将是最有利的。脂肪组织的组织基质血管部分(TSVF)是由嵌入细胞外基质的细胞的异质混合物组成。

伤口愈合和疤痕形成取决于多种因素。鉴于异常疤痕形成的影响,旨在改善疤痕形成的干预措施将是最有利的。脂肪组织的组织基质血管部分(TSVF)是由嵌入细胞外基质的细胞的异质混合物组成,含有参与伤口愈合过程的生长因子和细胞因子,例如,实质增殖、炎症、血管生成和基质重塑。近日,发表于Aesthet Surg J的一项前瞻性、双盲、安慰剂对照的随机试验旨在验证TSVF减少手术后疤痕形成的假设。

 

研究于2016年至2020年进行,纳入了 40 名乳房整形术患者,并随访1年。在乳房整形手术结束后,所有患者在1个乳房的水平疤痕的侧面 5cm处接受 tSVF,并在对侧乳房注射安慰剂,作为患者内部对照。主要结果是通过患者和观察者疤痕评估量表(POSAS)衡量疤痕质量。次要结果是通过照片评估和疤痕组织样本的组织学分析获得。

结果,40 名患者中有 34 名完成了随访。术后 6 个月时,根据 POSAS 问卷调查,注射 TSVF 明显改善了术后疤痕的外观。术后12个月时,没有观察到差异。根据对两组术后疤痕的照片和组织学分析的评估,注射 TSV F并未改善瘢痕。

综上所述,该研究结果表明,注射 TSVF 可改善伤口愈合,减少术后6个月的疤痕形成,但在 12 个月时没有看到任何明显的优势效果。这些结果表明,TSVF 可能只是早期伤口愈合和疤痕形成的一个加速器。未来的研究应关注这些早期过程,以阐明 TSVF 发挥其作用的具体机制。

原始出处:

Joris A van Dongen, et al., Tissue Stromal Vascular Fraction Improves Early Scar Healing: A Prospective Randomized Multicenter Clinical Trial. Aesthet Surg J. 2022 Jun 20;42(7):NP477-NP488. doi: 10.1093/asj/sjab431.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051803, encodeId=05fe205180353, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 10 18:29:31 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237844, encodeId=f27a123e84421, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d416160714, createdName=ms8000000185867059, createdTime=Wed Aug 10 15:40:34 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230230, encodeId=8426123023014, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Sun Jul 03 09:08:48 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309926, encodeId=b4e61309926ed, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394140, encodeId=976b1394140ff, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051803, encodeId=05fe205180353, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 10 18:29:31 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237844, encodeId=f27a123e84421, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d416160714, createdName=ms8000000185867059, createdTime=Wed Aug 10 15:40:34 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230230, encodeId=8426123023014, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Sun Jul 03 09:08:48 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309926, encodeId=b4e61309926ed, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394140, encodeId=976b1394140ff, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-08-10 ms8000000185867059

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2051803, encodeId=05fe205180353, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 10 18:29:31 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237844, encodeId=f27a123e84421, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d416160714, createdName=ms8000000185867059, createdTime=Wed Aug 10 15:40:34 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230230, encodeId=8426123023014, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Sun Jul 03 09:08:48 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309926, encodeId=b4e61309926ed, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394140, encodeId=976b1394140ff, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-03 xulv123

    认真学习~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2051803, encodeId=05fe205180353, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 10 18:29:31 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237844, encodeId=f27a123e84421, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d416160714, createdName=ms8000000185867059, createdTime=Wed Aug 10 15:40:34 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230230, encodeId=8426123023014, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Sun Jul 03 09:08:48 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309926, encodeId=b4e61309926ed, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394140, encodeId=976b1394140ff, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051803, encodeId=05fe205180353, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jan 10 18:29:31 CST 2023, time=2023-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237844, encodeId=f27a123e84421, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d416160714, createdName=ms8000000185867059, createdTime=Wed Aug 10 15:40:34 CST 2022, time=2022-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230230, encodeId=8426123023014, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Sun Jul 03 09:08:48 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309926, encodeId=b4e61309926ed, content=<a href='/topic/show?id=5e6926003ae' target=_blank style='color:#2F92EE;'>#伤口愈合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26003, encryptionId=5e6926003ae, topicName=伤口愈合)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394140, encodeId=976b1394140ff, content=<a href='/topic/show?id=7b29e0460b1' target=_blank style='color:#2F92EE;'>#疤痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70460, encryptionId=7b29e0460b1, topicName=疤痕)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Fri Jul 01 15:29:31 CST 2022, time=2022-07-01, status=1, ipAttribution=)]
    2022-07-01 HinsMax

相关威廉亚洲官网

二氧化碳激光点阵激光治疗红色杜洛克猪模型中厚层皮肤移植物挛缩的有效性和安全性

二氧化碳点阵激光在分层植皮后的疤痕管理中发挥着重要作用,它可以松解植皮挛缩,恢复表面的光滑度。

Orthopedics:切口愈合瘢痕更小,外观更好,可以选择皮肤粘结胶带

皮肤粘结胶带通常用于促进皮肤伤口的闭合和轻微裂伤。最近,组织粘合剂,如2-氰基丙烯酸辛酯,因其高抗拉强度,具有抑菌特性和,并可自发脱落而备受欢迎。

Laryngoscope:甲状腺术后的疤痕管理策略,哪项更优?

甲状腺术后的疤痕位于高度敏感和可见的解剖位置,其对外观的影响已成为患者术后满意度的最重要因素之一。近日,发表于Laryngoscope的一项目前瞻性随机试验比较了应用不同方案时的疤痕质量,并最终旨在找

Photodermatol Photoimmunol Photomed:血浆凝胶联合点阵式二氧化碳激光可有效治疗痤疮所致的瘢痕

寻常性痤疮所致的萎缩性痤疮后瘢痕往往永久且难治疗的。萎缩性痤疮后瘢痕的发病率高,对生活质量影响很大,对皮肤科医生来说也是一个治疗上的挑战。

Lasers Med Sci:剥脱性和非剥脱性激光都可有效改善萎缩性痤疮瘢痕

寻常痤疮是一种慢性顽固的皮肤炎症,在青少年甚至成年人中的发病率很高。痤疮疤痕是一种常见的美容并发症,可能会给患者带来生理和心理压力,影响患者的生活质量。

Aesthet Surg J:面部手术后立即长期使用组织胶水可有效减小疤痕体积

手术后疤痕的形成,尤其是疤痕外观的美容问题,是患者和临床医生关注的地方,大大影响病人的满意度。然而,可靠的皮肤支持方案是有限的。